According to EurekaAlert, Novo Biosciences Inc., a spinoff of the MDI Biological Laboratory in Bar Harbor, Maine, has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. “We believe MSI-1436 has enormous potential,” said Kevin Strange, Ph.D., CEO of Novo Biosciences and president of the MDI Biological Laboratory. “No drug now exists to treat heart attack. Heart disease is the the world’s leading killer. In order to advance MSI-1436 into clinical trials, we need to first test its effectiveness in a large animal model. We are deeply grateful to the National Heart, Lung, and Blood Institute for making this possible.” Read more
Related Posts
UMaine professor McGill receives top German research award
ORONO — University of Maine ecology professor Brian McGill was awarded the Humboldt Research Award, one of the most prestigious scientific...
Four Maine workforce programs could get $6.5M in fed funding
Four workforce training programs in Maine could receive nearly $6.5 million in federal funding through the markup of the fiscal year 2024 financial...
Music as medicine: FDA approves stroke damage therapy from Portland startup
Doctors may soon start writing an unconventional prescription to help stroke survivors regain their ability to walk: music. MedRhythms, a Portland...